T Cell Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type, Indication, and Geography

Description

List of Tables

According to our new research study on "T Cell Therapy Market Forecast (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis - by Modality, Therapy Type, and Indication," the T cell therapy market size was valued at US$ 2,754.00 million in 2022 and is expected to reach US$ 9,035.01 million by 2030. It is estimated to register a CAGR of 16.0% during 2020-2030.

One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. The growing burden of cancer worldwide and an increasing number of T cell therapy approvals drive the growth of the T cell therapy market. Also, rising number of car t-cell therapies in clinical trials is expected to fuel T cell therapy market growth in the coming years.

The current landscape for CAR T-cell therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.

In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics' proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.

JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.

Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).

ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).

Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity-adverse events commonly associated with CAR T-cell treatment.

Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the T cell therapy market.

By Modality, T Cell Therapy Market-Based Insights

Based on modality, the T cell therapy market is segmented into research and commercialized. In 2022, the commercialized segment held the larger share of the market. Moreover, the same segment is expected to grow fastest during the forecast period. An increase in product launches and a rise in awareness about the benefits of T cell therapy for cancer treatment fueling the growth of the commercialized segment.

By Therapy Type, T Cell Therapy Market -Based Insights

Based on therapy type, the T cell therapy market is bifurcated into CAR T cell therapy and T cell receptor (TCR)-based. In 2022, the CAR T cell therapy segment held the larger share of the market. Moreover, the same segment will grow at a significant growth rate during the forecast period. In the chimeric antigen receptor (CAR) T cell therapy technique, T cells obtained from patients are artificially bioengineered to express CARs that can identify and attach to the tumor cells. The companies are entering into strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches by companies operating in the CAR T cell segment, fueling the T cell therapy market growth. For instance, in 2022, FDA approved CARVYKTI manufactured by Janssen Biotech, Inc. CARVYKTI is a kind of therapy called CAR-T-which stands for chimeric antigen receptor T cell. CARVYKTI (ciltacabtagene autoleucel) is a treatment used for adult patients with bone marrow cancer called multiple myeloma. CARVYKTI treats adult patients with relapsed or refractory multiple myeloma after four or more former lines of therapy, comprising a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The World Health Organization (WHO), the European Cancer Patient Coalition, and the National Cancer Institute are a few of the major primary and secondary sources referred to while preparing the report on the T cell therapy market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the T cell therapy market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global T cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global T cell therapy market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Product Code: TIPRE00024331

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 T Cell Therapy Market, by Geography (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. T Cell Therapy Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 Global PEST Analysis

5. T Cell Therapy Market - Key Industry Dynamics

5.1 Market Drivers:
- 5.1.1 Growing Burden of Cancer Worldwide
- 5.1.2 Increasing Number of T-Cell Therapy Approvals
5.2 Market Restraints
- 5.2.1 Side-effects of CAR T-Cell Therapy
5.3 Market Opportunities
- 5.3.1 Growing Investment in T-Cell Therapy
5.4 Future Trends
- 5.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
5.5 Impact Analysis:

6. T Cell Therapy Market - Global Market Analysis

6.1 T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

7. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality

7.1 Overview
7.2 T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
7.3 Research
- 7.3.1 Overview
- 7.3.2 Research: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Commercialized
- 7.4.1 Overview
- 7.4.2 Commercialized: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

8.1 Overview
8.2 T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
8.3 CAR T-cell Therapy
- 8.3.1 Overview
- 8.3.2 CAR T-cell Therapy: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 T-cell Receptor (TCR)-based
- 8.4.1 Overview
- 8.4.2 T-cell Receptor (TCR)-based: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

9.1 Overview
9.2 T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
9.3 Hematologic Malignancies
- 9.3.1 Overview
- 9.3.2 Hematologic Malignancies: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.3 Global T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
9.4 Solid Tumor
- 9.4.1 Overview
- 9.4.2 Solid Tumor: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

10. T Cell Therapy Market - Geographical Analysis

10.1 North America T Cell Therapy Market, Revenue and Forecast To 2030
- 10.1.1 Overview
- 10.1.2 North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.3 North America: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.1.4 North America: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.1.5 North America: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.1.5.1 North America: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.1.5.2 North America T Cell Therapy Market, by Country
  - 10.1.5.3 US
    - 10.1.5.3.1 US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.5.3.2 US: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.1.5.3.3 US: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.5.3.4 US: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.5.3.4.1 US: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.1.5.4 Canada
    - 10.1.5.4.1 Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.5.4.2 Canada: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.1.5.4.3 Canada: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.5.4.4 Canada: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.5.4.4.1 Canada: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.1.5.5 Mexico
    - 10.1.5.5.1 Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.5.5.2 Mexico: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.1.5.5.3 Mexico: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.5.5.4 Mexico: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.5.5.4.1 Mexico: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.2 Europe T Cell Therapy Market, Revenue and Forecast to 2030
- 10.2.1 Overview
- 10.2.2 Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.2.3 Europe: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.2.4 Europe: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.2.5 Europe: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.2.5.1 Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.2 Europe T Cell Therapy Market, by Country
  - 10.2.5.3 UK
    - 10.2.5.3.1 UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.3.2 UK: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.3.3 UK: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.3.4 UK: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.3.4.1 UK: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.4 Germany
    - 10.2.5.4.1 Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.4.2 Germany: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.4.3 Germany: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.4.4 Germany: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.4.4.1 Germany: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.5 France
    - 10.2.5.5.1 France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.5.2 France: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.5.3 France: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.5.4 France: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.5.4.1 France: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.6 Italy
    - 10.2.5.6.1 Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.6.2 Italy: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.6.3 Italy: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.6.4 Italy: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.6.4.1 Italy: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.7 Spain
    - 10.2.5.7.1 Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.7.2 Spain: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.7.3 Spain: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.7.4 Spain: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.7.4.1 Spain: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.8 Rest of Europe
    - 10.2.5.8.1 Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.8.2 Rest of Europe: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.8.3 Rest of Europe: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.8.4 Rest of Europe: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.8.4.1 Rest of Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.3 Asia Pacific T Cell Therapy Market, Revenue and Forecast to 2030
- 10.3.1 Overview
- 10.3.2 Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.3.3 Asia Pacific: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.3.4 Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.3.5 Asia Pacific: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.3.5.1 Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.2 Asia Pacific T Cell Therapy Market, by Country
  - 10.3.5.3 China
    - 10.3.5.3.1 China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.3.2 China: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.3.3 China: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.3.4 China: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.3.4.1 China: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.4 Japan
    - 10.3.5.4.1 Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.4.2 Japan: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.4.3 Japan: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.4.4 Japan: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.4.4.1 Japan: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.5 Australia
    - 10.3.5.5.1 Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.5.2 Australia: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.5.3 Australia: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.5.4 Australia: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.5.4.1 Australia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.6 South Korea
    - 10.3.5.6.1 South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.6.2 South Korea: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.6.3 South Korea: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.6.4 South Korea: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.6.4.1 South Korea: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.7 Rest of Asia Pacific
    - 10.3.5.7.1 Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.7.2 Rest of Asia Pacific: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.7.3 Rest of Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.7.4 Rest of Asia Pacific: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.7.4.1 Rest of Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.4 Middle East & Africa T Cell Therapy Market, Revenue and Forecast to 2030
- 10.4.1 Overview
- 10.4.2 Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.4.3 Middle East & Africa: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.4.4 Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.4.5 Middle East & Africa: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.4.5.1 Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.4.5.2 Middle East & Africa T Cell Therapy Market, by Country
  - 10.4.5.3 Saudi Arabia
    - 10.4.5.3.1 Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.3.2 Saudi Arabia: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.4.5.3.3 Saudi Arabia: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.3.4 Saudi Arabia: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.3.4.1 Saudi Arabia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.4.5.4 Israel
    - 10.4.5.4.1 Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.4.2 Israel: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.4.5.4.3 Israel: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.4.4 Israel: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.4.4.1 Israel: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.4.5.5 Rest of Middle East & Africa
    - 10.4.5.5.1 Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.5.2 Rest of Middle East & Africa: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.4.5.5.3 Rest of Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.5.4 Rest of Middle East & Africa: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.5.4.1 Rest of Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.5 South & Central America T Cell Therapy Market, Revenue and Forecast to 2030
- 10.5.1 Overview
- 10.5.2 South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 10.5.2.1 Brazil
    - 10.5.2.1.1 Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.2.1.2 Brazil: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.5.2.1.3 Brazil: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.5.2.1.4 Brazil: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.5.2.1.4.1 Brazil: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)

11. T Cell Therapy Market-Industry Landscape

11.1 Overview
11.2 Growth Strategies in T Cell Therapy Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Immunocore Holdings Plc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Legend Biotech Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Janssen Global Services LLC
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Gilead Sciences Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Bristol-Myers Squibb Co
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Bluebird Bio Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Novartis AG
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 JW (Cayman) Therapeutics Co Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Cartesian Therapeutics Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Innovent Biologics Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms